The largest ever Italian biotech Series A round
NanoPhoria Bioscience secures €83.5 million Series A to advance breakthrough heart failure therapy
Advertisement
NanoPhoria Bioscience, a Milan-based biotech company, announced the successful first close of its €83.5 million Series A financing round. The round was led by XGEN Venture, Sofinnova Partners, and CDP Venture Capital, with Panakès Partners also investing and one other undisclosed investor joining the round.
The funding will propel NanoPhoria’s lead candidate, NP-MP1, through IND-enabling studies and early clinical development. NP-MP1 is a first-in-class peptide that targets cardiac L-type calcium channels to improve ejection fraction for the treatment of heart failure with reduced ejection fraction (HFrEF).
Delivered via NanoPhoria’s proprietary lung-to-heart nano-in-micro technology, NP-MP1 has demonstrated excellent efficacy in preclinical models of heart failure and aims to address a root cause of HFrEF by improving cardiac contractility. HFrEF is a condition affecting millions globally with a five-year mortality rate of approximately 40%.
“This financing is a transformational milestone for NanoPhoria,” said Claudio De Luca, CEO and co-founder. “It enables us to accelerate clinical development of NP-MP1 and expand our pipeline. Our innovative delivery platform allows us to target previously inaccessible cellular targets in the cardiomyocyte, thereby bringing us closer to delivering life-changing treatments for patients living with serious cardiac and other chronic conditions who are underserved by existing treatments. We are profoundly grateful to our scientific founders, our investors, our Board, and our Chair, Suman Shirodkar, whose vision and efforts have shaped NanoPhoria’s progress and ambition.”
This investment perfectly aligns with XGEN’s strategy to lead early financing rounds in the most innovative Italian startups that address true medical needs,” said Paolo Fundarò, Managing Partner at XGEN Venture. “NanoPhoria’s science provides a novel, and viable, way of delivering highly potent therapeutics directly to the heart and we look forward to working alongside such a fantastic syndicate of investors.”
“NanoPhoria’s platform has the potential to redefine treatment paradigms in cardiovascular and other chronic diseases which is why we are excited to invest in this company,” added Henrijette Richter, Managing Partner at Sofinnova Partners. “This financing builds on the early support of my colleague Lucia Faccio, Partner in the Sofinnova Telethon Strategy, whose role was instrumental in supporting the company in its early days to take shape. The investment reflects Sofinnova’s broader commitment to backing world-class science across Europe, from early-stage company creation to late-stage growth.”
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.